Nature is endowed with catalysts capable of an unprecedented diversity of biotransformations, beyond the capabilities of synthetic chemistries. In a biotechnological context, there is a growing and emerging need to tap this catalytic potential. CYP (cytochrome P450) represents a superfamily of enzymes capable of a diverse array of catalytic activities. Distinct members are engaged in biosynthetic reactions within many organisms, while others have a role in the detoxification of foreign compounds. The latter substrates include medicines, pollutants, pesticides, carcinogens, perfumes and herbicides, representing considerable applied importance for pharmacology and toxicology. CYPs show a high degree of stereo-and regio-specificity for their reactions, which have wide industrial applications. Recombinant CYPs are commonly expressed as active recombinant cytosolic forms in Escherichia coli. However, selective permeability of E. coli to many substrates and products can cause problems with product recovery when using whole-cell systems. To overcome these problems, we have been developing approaches to facilitate export of functional recombinant haemoproteins to the inner membrane, periplasm and the outer membrane of E. coli. Here, we describe the progress in relation to cytochrome b 5 and CYPs.
topogenic signals for periplasmic export, (ii) periplasmic haem delivery and its assembly with the exported apo form to generate active holo-haemoprotein, (iii) the need for source and supply of electrons by suitable reductase(s) for CYP catalysis, and (iv) substrate accessibility and extracellular discharge of product(s).
E. coli has at least two well-defined cellular compartments, the inner membrane-enclosed cytoplasm, and the periplasmic space partitioned between the inner and outer membrane. The vast majority of the periplasmically localized proteins, as well as inner and outer membrane proteins, which are initially synthesized in the cytoplasm, are vectorially discharged from the cytoplasm by the sec-dependent pre-protein translocation system located in the inner membrane. Exported proteins are synthesized as precursor forms carrying an N-terminal extension known as signal peptides or signal sequences [7] . Such fully synthesized precursor proteins are initially maintained in an unfolded or translocation-competent state with the aid of molecular chaperones such as SecB or SRP (signal recognition particle) prior to its engagement with the translocon. The E. coli Sec translocase is composed of the peripheral SecA and membrane proteins SecYEGDFYajC. SecA protein, a cytoplasmic ATPase, binds to the pre-protein via a crucial interaction involving recognition of the signal sequence [8] . Both the N-and H-domains of the signal sequence are essential for precursor recognition by SecA, which then binds SecYEA complex with a high affinity to form the aqueous protein-conducting channel in the inner membrane. In this bound complex, SecA functions as an ATP-dependent motor protein [9, 10] that sequentially drives unfolded polypeptide across the protein-aligned membrane pore through the use of the proton-motive force. Either during or following complete polypeptide translocation, the transposed SS (signal sequence) is cleaved off by an exocytoplasmic signal peptidase I. Although, by default, protein localization occurs in the periplasmic space, additional topogenic signals may facilitate integration in the cytoplasmic membrane [11] or further export to the outer membrane [12] . To investigate the feasibility of exporting haem-assembled CYP to various sublocations in E. coli, we have employed cytochrome b 5 and P450s as model proteins.
Targeting of topogenically engineered cytochrome b 5 to evaluate haem accessibility to peripheral E. coli compartments By applying the topogenic rules to cytochrome b 5 , it has proved possible to engineer artificially ( Figure 1A ) and efficiently target this mammalian model haemoprotein to almost all compartments of E. coli ( Figure 1B) ; this system, referred to as the PINK expression system, has a key advantage in that recombinant forms of the cytochrome are readily detectable and quantifiable by simple visual pink coloration of the bacterium [13] . The native cytochrome b 5 is a highly conserved, endoplasmic reticulum-bound protein. The amphipathic haemoprotein consists of two domains: a soluble, haem-binding core domain (C; ∼100 residues) and a Cterminal membrane anchor (T; ∼35 residues), and it belongs to a class of widespread, integral proteins with a monotopic membrane (N out -C in ) arrangement in which the globular enzymically active domain is laterally disposed facing the cytoplasm [14] . The endoplasmic reticulum isoform is a multifunctional protein participating in a variety of electron transfer reactions involving desaturation of fatty acids and sterol and xenobiotic hydroxylations. Transmembrane anchorage is provided by an insertion sequence, also capable of acting as a stop-transfer sequence, comprising a stretch of 20 uncharged amino acid residues at the C-terminus. The mode of tail anchorage in the endoplasmic reticulum lipid bilayer determines spatial positioning of the globular domain for its allosteric interaction with other P450 partners [15] .
Expression in E. coli of the globular form (C) [16] and the full-length native (CT) resulted in production of cytosolic forms, whereby the C form was accumulated as a soluble form and CT was integrally associated in the inner membrane with the C domain laterally facing inwards. Appendage of the secretory SS of E. coli alkaline phosphatase to the C form directed efficient export of the processed protein to the periplasm [17] . Selective discharge of the periplasmically exported C into the growth medium can be ensured by supplementation of defined amounts of glycine in the growth medium [18] , which generates enlarged pores in the outer membrane; glycine interferes with the biosynthesis of cell wall by acting as a structural analogue of L-and D-alanine found in the peptide units of peptidoglycan. A construct involving appendage of the SS to CT generated an unprocessed precursor chimaera that was integrally anchored in the cytoplasmic membrane with the haem-binding domain displaced towards the periplasmic space. Precursor processing of the translocated globular domain was aborted due to intercalation of the transmembrane C-terminal anchor (acting as a stoptransfer sequence) with the N-terminal signal peptide (Figure 1A) , which in turn masked the accessibility of the cleavage site to signal peptidase I [19] . More interestingly, the globular C form can even be selectively exported to the outer membrane (see Figure 1C , vi) by N-terminal appendage of the transit peptide of the small subunit of ribulose-1,5-bisphosphate carboxylase [20] .
Demand-dependent haem delivery is met in the periplasmic zones of E. coli
Significantly high yields of the haemoprotein (10-20% of the total cellular protein) in the entire engineered clone lines were visually demonstrated by the relative intensity of pink colour ( Figure 1C ). The engineered cytochrome topogenesis provides unequivocal evidence that haem for holo-haemoprotein biogenesis can be furnished in each of the bacterial compartments in the absence of supplementation of haem precursors. The significant build-up of the apo-cytochrome b 5 and the ensuing time lag (usually 4-5 h) in the detectable appearance of holo-cytochrome b 5 was also indicative of absence of a readily available haem pool within each compartment. Rather, haem provision appeared to have triggered accrual of apo-cytochrome b 5 . The production of all haem intermediates would be expected to occur exclusively in the cytosol where the complete hem-encoded pathway is localized [21] . De novo synthesis and independent haem transport by the HelABCD transporter into the periplasmic zone [22] was initiated by the apo-cytochrome b 5 acting as a sink. More interestingly, in each of the engineered clone lines, the proportion of the haemoprotein formed was invariably approx. 70% of the combined estimated pools of the holo and apo forms, again implying that haem delivery to each of the compartments was in direct proportion to that demanded by the arrival of the recombinant cytochrome b 5 . The variations in the intensity of the visually detected pink colours ( Figure 1C) do not reflect the apparent amount of the quantifiable holo haem targeted in the related compartment. Rather the 'pink' trend of the recombinant protein in different compartments is related to the apparent transparency of light through various cellular zones.
Targeting of functional CYPs to the periplasmic space
CYP105D1 is a unique soluble CYP of Streptomyces griseus that catalyses the transformation of an enormous diversity of structurally complex xenobiotics [23] . This mono-oxygenase system is analogous to human CYP3A4, the major xenobiotic-metabolizing CYP form in the liver, in its diverse substrate range and thus raises possibilities of convergent evolution of active site topology [24] . CYP105D1was appended at its N-terminus to the SS of E. coli alkaline phosphatase. The chimaeric P450 construct was placed under the transcriptional control of the native phoA promoter in a prokaryotic expression vector. Induction of the haemoprotein by heterologous expression in E. coli following growth in a phosphate-limited medium resulted in abundant synthesis of recombinant CYP105D1 as detected by oxidized-reduced difference spectra of the CO-haemoprotein. The signal-appended CYP105D1 was translocated across the bacterial inner membrane by the sec-dependent pathway and processed to yield haem-incorporated P450 within the periplasmic space. The levels of production of the functional haemoprotein were a magnitude higher than those reported previously for expression of the cytosolic form of CYP105D1 [23] .
Export of CYP105D1 in E. coli when cultured aerobically resulted in significant accumulation of uroporphyrin I [25] . This arose from catalytic oxidative conversion of uroporphyrinogen I into uroporphyrin I in the periplasm of E. coli (Figure 2 ). Its progressive induction in the presence of 5-aminolevulinic acid-supplemented medium was accompanied by an accumulation of over a 100-fold higher amount of uroporphyrin I in the periplasm relative to cells lacking CYP105D1. Expression of a cytoplasmic-resident engineered CYP105D1 at a comparative level to the secreted form was far less effective in promoting porphyrin accumulation in the periplasm. Expression at 10-fold molar excess over the exported CYP105D1 of another periplasmically exported haemoprotein, the globular core of cytochrome b 5 , did not substitute the role of the periplasmically localized CYP105D1 in promoting porphyrin production. This, therefore, eliminated the possibility that uroporphyrin accumulation was merely a result of increased haemoprotein synthesis. Moreover, in the strain that secreted CYP105D1, uroporphyrin production was considerably reduced by azole-based P450 inhibitors. Production of both holo CYP105D1 and uroporphyrin was dependent on 5-aminolevulinic acid, except that at higher concentrations this resulted in a decrease in uroporphyrin. These findings demonstrated for the first time the in vivo generation of a porphyric state in E. coli. Cytoplasmically generated uroporphyrinogen was transported to the periplasm where CYP105D1 oxidatively converted it into uropophyrin (Figure 2 ). The periplasmic Shown are uroporphyrinogen I (UROgen I) production from haem biosynthetic pathway, translocation of uroporphyrinogen I to E. coli periplasm and CYP105D1-catalysed conversion of uroporphyrinogen I into uroporphyrin I (URO I). HelABCD, haem translocator; PPT, pre-protein translocase; COPROgen, co-proporphyrinogen; pre-CYP105D1, precursor of CYP105D1; PBG, porphobilinogen; HMB, hydroxymethylbilane; IM, inner membrane; OM, outer membrane. The thickness of the arrowed lines indicates the extent of metabolite flow.
reaction involving production of uropophyrin I would be expected to require reducing equivalent(s) and molecular oxygen for the P450 catalysis and a yet unidentified reductase system to transfer the reducing equivalents to CYP105D1. Reducing equivalents such as NADH or NADPH are unlikely to be present in the periplasmic space but electrons could be scavenged from the electron transport chain or other periplasmic oxidoreductant reactions. However, electron transfer to the heterologous CYP105D1 must require a reductase, most likely a ferredoxin reduction-type system. Genomic analysis of E. coli suggests the presence of a periplasmic ferredoxin-type reductase that uses a TAT (twin-arginine translocase)-dependent export pathway. The removal of six hydrogen atoms from uroporphyrinogen I, two from the pyrrolic nitrogens and four from the methene carbons, would result in the formation of uroporphyrin I. As yet, the mechanism for the mediation of uroporphyrinogen oxidation by CYP remains unknown.
In vitro and ex vivo metabolic activity studies showed that the periplasmically located CYP105D1 readily catalysed NADH-dependent oxidation of the xenobiotic compounds benzo[a]pyrene and erythromycin, thus indicating the presence in the E. coli periplasm of the necessary endogenous redox partners [23] . This system offers substantial advantages for the application of P450 enzymes to whole-cell biotransformation strategies, where the ability of cells to take up substrates or discard products may be limited. The ability to localize CYPs in the more hospitable environment of the periplasm opens the way to produce high levels of proteins (600 nmol/l of culture) where post-translational assembly of haem with the translocated apoprotein can be further exploited. Along the same principles, we have re-engineered the versatile human CYP1A1 [26] and the human CYP17 as secretory forms following the removal of their N-terminal membrane anchors. Both forms have been over-produced in active forms. Similarly, the uroporphyric states have been observed with periplasmic expression of CYP17 and CYP1A1 in E. coli. While these findings have significant implications in the ontogenesis of human uroporphyria-related diseases, the in vivo CYPs promise to offer considerable biotechnological potentials in pharmaceutical applications.
